Inhibitors of CSF1R or its ligand CSF1 interfere with tumor-promoting TAMs or other myeloid cells in the TME and are currently being tested in clinical trials for treatment of several types of malignancies, such as CRC, melanoma or ovarian cancer (reviewed in refs. [11, 77]). Here, CSF1R is linked to ovarian cancer.